When you’re evaluating the efficacy of a therapy or drug target, Veridex CRS gives you the power to focus on important biomarkers. Our tumor phenotyping reagents (TPRs) allow you to analyze the cell’s proteome, genome or gene expression. And using specific TPRs such as HER-2/neu, EGFr, or IGF-1R, we give you the ability to determine if rare cells are intact or apoptotic, and provide other unique and compelling insight. You can also re-interrogate those same cells at multiple points along the pathway to see activity at the genetic level.
This site is published by Veridex, LLC, which is solely responsible for its contents. © Veridex, LLC 2011. This site is intended for use by residents of the United States of America.
This information is intended for biotech, pharmaceutical, and/or academic researchers. The products/services discussed are for research use only and not for use in diagnostic
procedures. Last updated on: 22 April 2013